Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer
NCT07130643
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
HR+/HER2- Breast Cancer
Interventions
DRUG:
CDK4/6 inhibitors+Endocrine Therapy
Sponsor
Xinhong Wu, PhD